Insertional oncogenesis by non-acute retroviruses: Implications for gene therapy

Viruses

Volumn 3, Issue 4, 2011, Pages 398-422

  Fan, Hung ^a   Johnson, Chassidy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Nonacute retrovirus; Oncogene; Oncogenesis; Proto oncogene; Retroviral vector; Retrovirus

Indexed keywords

ADENOSINE DEAMINASE; BETA GLOBIN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

BETA THALASSEMIA; CANCER GROWTH; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INSERTION; GENE INTERACTION; HUMAN; IMMUNE DEFICIENCY; LONG TERMINAL REPEAT; NONHUMAN; PROMOTER REGION; PROTO ONCOGENE; RETROVIRUS; REVIEW; T CELL LEUKEMIA; VIRAL GENE DELIVERY SYSTEM; VIRUS CARCINOGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSFORMATION;

ANIMALS; GENE THERAPY; HUMANS; MICE; MUTAGENESIS, INSERTIONAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; VIRUS INTEGRATION;

ANIMALIA; MUS;

EID: 79955663440     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3040398     Document Type: Review

References (132)

1. Urisman, A.; Molinaro, R.J.; Fischer, N.; Plummer, S.J.; Casey, G.; Klein, E.A.; Malathi, K.; Magi-Galluzzi, C.; Tubbs, R.R.; Ganem, D.; Silverman, R.H.; Derisi, J.L. Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant. PLoS Pathog. 2006, 2, e25.
2. Dong, B.; Kim, S.; Hong, S.; Das Gupta, J.; Malathi, K.; Klein, E.A.; Ganem, D.; Derisi, J.L.; Chow, S.A.; Silverman, R.H. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 1655-1660.
3. Hue, S.; Gray, E.R.; Gall, A.; Katzourakis, A.; Tan, C.P.; Houldcroft, C.J.; McLaren, S.; Pillay, D.; Futreal, A.; Garson, J.A.; Pybus, O.G.; Kellam, P.; Towers, G.J. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010, 7, 111.
4. Schlaberg, R.; Choe, D.J.; Brown, K.R.; Thaker, H.M.; Singh, I.R. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 16351-16356.
5. Fischer, N.; Hellwinkel, O.; Schulz, C.; Chun, F.K.; Huland, H.; Aepfelbacher, M.; Schlomm, T. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J. Clin. Virol. 2008, 43, 277-283.
6. Lombardi, V.C.; Ruscetti, F.W.; Das Gupta, J.; Pfost, M.A.; Hagen, K.S.; Peterson, D.L.; Ruscetti, S.K.; Bagni, R.K.; Petrow-Sadowski, C.; Gold, B.; Dean, M.; Silverman, R.H.; Mikovits, J.A. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326, 585-589.
7. Aloia, A.L.; Sfanos, K.S.; Isaacs, W.B.; Zheng, Q.; Maldarelli, F.; De Marzo, A.M.; Rein, A. XMRV: A New Virus in Prostate Cancer? Cancer Res. 2010, 70, 10028-10033.
8. Lo, S.C.; Pripuzova, N.; Li, B.; Komaroff, A.L.; Hung, G.C.; Wang, R.; Alter, H.J. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc. Natl. Acad. Sci. U. S. A. 107, 15874-15879.
9. Groom, H.C.; Boucherit, V.C.; Makinson, K.; Randal, E.; Baptista, S.; Hagan, S.; Gow, J.W.; Mattes, F.M.; Breuer, J.; Kerr, J.R.; Stoye, J.P.; Bishop, K.N. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010, 7, 10.
10. Smith, R.A. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 2010, 7, 112.
11. Coffin, J.; Hughes, S.; Varmus, H. Retroviruses; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1997.
12. Bushman, F.; Lewinski, M.; Ciuffi, A.; Barr, S.; Leipzig, J.; Hannenhalli, S.; Hoffmann, C. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 2005, 3, 848-858.
13. Rosenberg, N.; Jolicoeur, P. Retroviral pathogenesis. In Retroviruses; Coffin, J., Hughes, S.H., Varmus, H.E., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1997; pp. 475-585.
14. Duesberg, P.H.; Vogt, P.K. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc. Natl. Acad. Sci. U. S. A. 1970, 67, 1673-1680.
15. Temin, H.M.; Rubin, H. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. Virology 1958, 6, 669-688.
16. Brugge, J.S.; Erikson, R.L. Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 1977, 269, 346-348.
17. Collett, M.S.; Erikson, R.L. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. U. S. A. 1978, 75, 2021-2024.
18. Collett, M.S.; Purchio, A.F.; Erikson, R.L. Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine. Nature 1980, 285, 167-169.
19. Hunter, T.; Sefton, B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. U. S. A. 1980, 77, 1311-1315.
20. Sheiness, D.; Fanshier, L.; Bishop, J.M. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J. Virol. 1978, 28, 600-610.
21. Graf, T.; Beug, H. Role of the v-erbA and v-erbB oncogenes of avian erythroblastosis virus in erythroid cell transformation. Cell 1983, 34, 7-9.
22. Stehelin, D.; Varmus, H.E.; Bishop, J.M.; Vogt, P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976, 260, 170-173.
23. Shih, T.Y.; Papageorge, A.G.; Stokes, P.E.; Weeks, M.O.; Scolnick, E.M. Guanine nucleotidebinding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature 1980, 287, 686-691.
24. Ellis, R.W.; Defeo, D.; Shih, T.Y.; Gonda, M.A.; Young, H.A.; Tsuchida, N.; Lowy, D.R.; Scolnick, E.M. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 1981, 292, 506-511.
25. Willingham, M.C.; Pastan, I.; Shih, T.Y.; Scolnick, E.M. Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell 1980, 19, 1005-1014.
26. Huleihel, M.; Goldsborough, M.; Cleveland, J.; Gunnell, M.; Bonner, T.; Rapp, U.R. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol. Cell Biol. 1986, 6, 2655-2662.
27. Rapp, U.R.; Goldsborough, M.D.; Mark, G.E.; Bonner, T.I.; Groffen, J.; Reynolds, F.H., Jr.; Stephenson, J.R. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. U. S. A. 1983, 80, 4218-4222.
28. Vennstrom, B.; Sheiness, D.; Zabielski, J.; Bishop, J.M. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 1982, 42, 773-779.
29. Alitalo, K.; Ramsay, G.; Bishop, J.M.; Pfeifer, S.O.; Colby, W.W.; Levinson, A.D. Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature 1983, 306, 274-277.
30. Van Beveren, C.; van Straaten, F.; Curran, T.; Muller, R.; Verma, I.M. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 1983, 32, 1241-1255.
31. van Straaten, F.; Muller, R.; Curran, T.; Van Beveren, C.; Verma, I.M. Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc. Natl. Acad. Sci. U. S. A. 1983, 80, 3183-3187.
32. Bohmann, D.; Bos, T.J.; Admon, A.; Nishimura, T.; Vogt, P.K.; Tjian, R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987, 238, 1386-1392.
33. Maki, Y.; Bos, T.J.; Davis, C.; Starbuck, M.; Vogt, P.K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 2848-2852.
34. Bellacosa, A.; Testa, J.R.; Staal, S.P.; Tsichlis, P.N. A retroviral oncogene, akt, encoding a serinethreonine kinase containing an SH2-like region. Science 1991, 254, 274-277.
35. Franke, T.F.; Yang, S.I.; Chan, T.O.; Datta, K.; Kazlauskas, A.; Morrison, D.K.; Kaplan, D.R.; Tsichlis, P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase. Cell 1995, 81, 727-736.
36. Tabin, C.J.; Bradley, S.M.; Bargmann, C.I.; Weinberg, R.A.; Papageorge, A.G.; Scolnick, E.M.; Dhar, R.; Lowy, D.R.; Chang, E.H. Mechanism of activation of a human oncogene. Nature 1982, 300, 143-149.
37. Reddy, E.P.; Reynolds, R.K.; Santos, E.; Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982, 300, 149-152.
38. Alitalo, K.; Schwab, M.; Lin, C.C.; Varmus, H.E.; Bishop, J.M. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1983, 80, 1707-1711.
39. Schwab, M.; Alitalo, K.; Klempnauer, K.H.; Varmus, H.E.; Bishop, J.M.; Gilbert, F.; Brodeur, G.; Goldstein, M.; Trent, J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305, 245-248.
40. Schwab, M.; Alitalo, K.; Varmus, H.E.; Bishop, J.M.; George, D. A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature 1983, 303, 497-501.
41. Dalla-Favera, R.; Martinotti, S.; Gallo, R.C.; Erikson, J.; Croce, C.M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 1983, 219, 963-967.
42. Marcu, K.B.; Harris, L.J.; Stanton, L.W.; Erikson, J.; Watt, R.; Croce, C.M. Transcriptionally active c-myc oncogene is contained within NIARD, a DNA sequence associated with chromosome translocations in B-cell neoplasia. Proc. Natl. Acad. Sci. U. S. A. 1983, 80, 519-523.
43. Nowell, P.; Finan, J.; Dalla-Favera, R.; Gallo, R.C.; ar-Rushdi, A.; Romanczuk, H.; Selden, J.R.; Emanuel, B.S.; Rovera, G.; Croce, C.M. Association of amplified oncogene c-myc with an abnormally banded chromosome 8 in a human leukaemia cell line. Nature 1983, 306, 494-497.
44. Hayward, W.S.; Neel, B.G.; Astrin, S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290, 475-480.
45. Payne, G.S.; Bishop, J.M.; Varmus, H.E. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature 1982, 295, 209-214.
46. Selten, G.; Cuypers, H.T.; Zijlstra, M.; Melief, C.; Berns, A. Involvement of c-myc in MuLVinduced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J. 1984, 3, 3215-3222.
47. Steffen, D. Proviruses are adjacent to c-myc in some murine leukemia virus-induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 1984, 81, 2097-2101.
48. Fung, Y.K.; Lewis, W.G.; Crittenden, L.B.; Kung, H.J. Activation of the cellular oncogene c-erbB by LTR insertion: molecular basis for induction of erythroblastosis by avian leukosis virus. Cell 1983, 33, 357-368.
49. Nilsen, T.W.; Maroney, P.A.; Goodwin, R.G.; Rottman, F.M.; Crittenden, L.B.; Raines, M.A.; Kung, H.J. c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an amino-truncated EGF receptor. Cell 1985, 41, 719-726.
50. Raines, M.A.; Lewis, W.G.; Crittenden, L.B.; Kung, H.J. c-erbB activation in avian leukosis virus-induced erythroblastosis: clustered integration sites and the arrangement of provirus in the c-erbB alleles. Proc. Natl. Acad. Sci. U. S. A. 1985, 82, 2287-2291.
51. Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31, 99-109.
52. Peters, G.; Brookes, S.; Smith, R.; Dickson, C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 1983, 33, 369-377.
53. Dickson, C.; Smith, R.; Brookes, S.; Peters, G. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell 1984, 37, 529-536.
54. Gallahan, D.; Kozak, C.; Callahan, R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J. Virol. 1987, 61, 218-220.
55. Katoh, M. WNT and FGF gene clusters (review). Int. J. Oncol. 2002, 21, 1269-1273.
56. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159-170.
57. Cuypers, H.T.; Selten, G.; Quint, W.; Zijlstra, M.; Maandag, E.R.; Boelens, W.; van Wezenbeek, P.; Melief, C.; Berns, A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984, 37, 141-150.
58. Breuer, M.L.; Cuypers, H.T.; Berns, A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 1989, 8, 743-748.
59. Jolicoeur, P.; Villeneuve, L.; Rassart, E.; Kozak, C. Mouse chromosomal mapping of a murine leukemia virus integration region (Mis-1) first identified in rat thymic leukemia. J. Virol. 1985, 56, 1045-1048.
60. Moreau-Gachelin, F.; Tavitian, A.; Tambourin, P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 1988, 331, 277-280.
61. Paul, R.; Schuetze, S.; Kozak, S.L.; Kabat, D. A common site for immortalizing proviral integrations in Friend erythroleukemia: molecular cloning and characterization. J. Virol. 1989, 63, 4958-4961.
62. Ben-David, Y.; Giddens, E.B.; Bernstein, A. Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 1332-1336.
63. Copeland, N.G.; Jenkins, N.A. Myeloid leukemia: Disease genes and mouse models. Prog. Exp. Tumor Res. 1999, 35, 53-63.
64. Copeland, N.G.; Jenkins, N.A. Retroviral integration in murine myeloid tumors to identify Evi-1, a novel locus encoding a zinc-finger protein. Adv. Cancer Res. 1990, 54, 141-157.
65. Mouse Retroviral Tagged Cancer Gene Database. Available online: http://RTCGD.ncifcrf.gov (accessed on 1 March 2011).
66. Akagi, K.; Suzuki, T.; Stephens, R.M.; Jenkins, N.A.; Copeland, N.G. RTCGD: Retroviral tagged cancer gene database. Nucleic Acids Res. 2004, 32, D523-D527.
67. Holland, C.A.; Thomas, C.Y.; Chattopadhyay, S.K.; Koehne, C.; O'Donnell, P.V. Influence of enhancer sequences on thymotropism and leukemogenicity of mink cell focus-forming viruses. J. Virol. 1989, 63, 1284-1292.
68. Lenz, J.; Celander, D.; Crowther, R.L.; Patarca, R.; Perkins, D.W.; Haseltine, W.A. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 1984, 308, 467-470.
69. Chatis, P.A.; Holland, C.A.; Silver, J.E.; Frederickson, T.N.; Hopkins, N.; Hartley, J.W. A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus. J. Virol. 1984, 52, 248-254.
70. Li, Y.; Golemis, E.; Hartley, J.W.; Hopkins, N. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 1987, 61, 693-700.
71. Short, M.K.; Okenquist, S.A.; Lenz, J. Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J. Virol. 1987, 61, 1067-1072.
72. Mester, J.; Wagenaar, E.; Sluyser, M.; Nusse, R. Activation of int-1 and int-2 mammary oncogenes in hormone-dependent and-independent mammary tumors of GR mice. J. Virol. 1987, 61, 1073-1078.
73. Cuypers, H.T.; Selten, G.C.; Zijlstra, M.; de Goede, R.E.; Melief, C.J.; Berns, A.J. Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes. J. Virol. 1986, 60, 230-241.
74. van Lohuizen, M.; Verbeek, S.; Krimpenfort, P.; Domen, J.; Saris, C.; Radaszkiewicz, T.; Berns, A. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989, 56, 673-682.
75. van Lohuizen, M.; Verbeek, S.; Scheijen, B.; Wientjens, E.; van der Gulden, H.; Berns, A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65, 737-752.
76. van der Lugt, N.M.; Domen, J.; Verhoeven, E.; Linders, K.; van der Gulden, H.; Allen, J.; Berns, A. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J. 1995, 14, 2536-2544.
77. Mikkers, H.; Allen, J.; Knipscheer, P.; Romeijn, L.; Hart, A.; Vink, E.; Berns, A. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat. Genet. 2002, 32, 153-159.
78. Girard, L.; Hanna, Z.; Beaulieu, N.; Hoemann, C.D.; Simard, C.; Kozak, C.A.; Jolicoeur, P. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 1996, 10, 1930-1944.
79. Stewart, M.; Cameron, E.; Campbell, M.; McFarlane, R.; Toth, S.; Lang, K.; Onions, D.; Neil, J.C. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int. J. Cancer 1993, 53, 1023-1030.
80. Stewart, M.; Terry, A.; Hu, M.; O'Hara, M.; Blyth, K.; Baxter, E.; Cameron, E.; Onions, D.E.; Neil, J.C. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 8646-8651.
81. Stewart, M.; Mackay, N.; Hanlon, L.; Blyth, K.; Scobie, L.; Cameron, E.; Neil, J.C. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res. 2007, 67, 5126-5133.
82. Kool, J.; Uren, A.G.; Martins, C.P.; Sie, D.; de Ridder, J.; Turner, G.; van Uitert, M.; Matentzoglu, K.; Lagcher, W.; Krimpenfort, P.; et al. Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. Cancer Res. 2010, 70, 520-531.
83. Tanaka, M.; Jin, G.; Yamazaki, Y.; Takahara, T.; Takuwa, M.; Nakamura, T. Identification of candidate cooperative genes of the Apc mutation in transformation of the colon epithelial cell by retroviral insertional mutagenesis. Cancer Sci. 2008, 99, 979-985.
84. Savard, P.; DesGroseillers, L.; Rassart, E.; Poirier, Y.; Jolicoeur, P. Important role of the long terminal repeat of the helper Moloney murine leukemia virus in Abelson virus-induced lymphoma. J. Virol. 1987, 61, 3266-3275.
85. Poirier, Y.; Kozak, C.; Jolicoeur, P. Identification of a common helper provirus integration site in Abelson murine leukemia virus-induced lymphoma DNA. J. Virol. 1988, 62, 3985-3992.
86. Jiang, X.; Hanna, Z.; Kaouass, M.; Girard, L.; Jolicoeur, P. Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J. Virol. 2002, 76, 9046-9059.
87. Bear, S.E.; Bellacosa, A.; Lazo, P.A.; Jenkins, N.A.; Copeland, N.G.; Hanson, C.; Levan, G.; Tsichlis, P.N. Provirus insertion in Tpl-1, an Ets-1-related oncogene, is associated with tumor progression in Moloney murine leukemia virus-induced rat thymic lymphomas. Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 7495-7499.
88. Patriotis, C.; Makris, A.; Bear, S.E.; Tsichlis, P.N. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 2251-2255.
89. Flubacher, M.M.; Bear, S.E.; Tsichlis, P.N. Replacement of interleukin-2 (IL-2)-generated mitogenic signals by a mink cell focus-forming (MCF) or xenotropic virus-induced IL-9-dependent autocrine loop: Implications for MCF virus-induced leukemogenesis. J. Virol. 1994, 68, 7709-7716.
90. Gilks, C.B.; Bear, S.E.; Grimes, H.L.; Tsichlis, P.N. Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Mol. Cell Biol. 1993, 13, 1759-1768.
91. Heard, J.M.; Fichelson, S.; Sola, B.; Martial, M.A.; Varet, B.; Levy, J.P. Multistep virus-induced leukemogenesis in vitro: description of a model specifying three steps within the myeloblastic malignant process. Mol. Cell Biol. 1984, 4, 216-220.
92. Sola, B.; Fichelson, S.; Bordereaux, D.; Tambourin, P.E.; Gisselbrecht, S. fim-1 and fim-2: Two new integration regions of Friend murine leukemia virus in myeloblastic leukemias. J. Virol. 1986, 60, 718-725.
93. Gisselbrecht, S.; Fichelson, S.; Sola, B.; Bordereaux, D.; Hampe, A.; Andre, C.; Galibert, F.; Tambourin, P. Frequent c-fms activation by proviral insertion in mouse myeloblastic leukaemias. Nature 1987, 329, 259-261.
94. Ben-David, Y.; Lavigueur, A.; Cheong, G.Y.; Bernstein, A. Insertional inactivation of the p53 gene during friend leukemia: a new strategy for identifying tumor suppressor genes. New Biol. 1990, 2, 1015-1023.
95. Mowat, M.; Cheng, A.; Kimura, N.; Bernstein, A.; Benchimol, S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 1985, 314, 633-636.
96. Largaespada, D.A.; Shaughnessy, J.D. Jr.; Jenkins, N.A.; Copeland, N.G. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J. Virol. 1995, 69, 5095-5102.
97. Nason-Burchenal, K.; Wolff, L. Activation of c-myb is an early bone-marrow event in a murine model for acute promonocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 1619-1623.
98. Shen-Ong, G.L.; Wolff, L. Moloney murine leukemia virus-induced myeloid tumors in adult BALB/c mice: Requirement of c-myb activation but lack of v-abl involvement. J. Virol. 1987, 61, 3721-3725.
99. Wolff, L.; Mushinski, J.F.; Shen-Ong, G.L.; Morse, H.C., 3rd. A chronic inflammatory response. Its role in supporting the development of c-myb and c-myc related promonocytic and monocytic tumors in BALB/c mice. J. Immunol. 1988, 141, 681-689.
100. Belli, B.; Wolff, L.; Nazarov, V.; Fan, H. Proviral activation of the c-myb proto-oncogene is detectable in preleukemic mice infected neonatally with Moloney murine leukemia virus but not in resulting end stage T lymphomas. J. Virol. 1995, 69, 5138-5141.
101. Clurman, B.E.; Hayward, W.S. Multiple proto-oncogene activations in avian leukosis virusinduced lymphomas: evidence for stage-specific events. Mol. Cell Biol. 1989, 9, 2657-2664.
102. Faraoni, I.; Antonetti, F.R.; Cardone, J.; Bonmassar, E. miR-155 gene: A typical multifunctional microRNA. Biochim. Biophys. Acta 2009, 1792, 497-505.
103. Bolisetty, M.T.; Dy, G.; Tam, W.; Beemon, K.L. Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J. Virol. 2009, 83, 12009-12017.
104. Landais, S.; Landry, S.; Legault, P.; Rassart, E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res. 2007, 67, 5699-5707.
105. Lum, A.M.; Wang, B.B.; Li, L.; Channa, N.; Bartha, G.; Wabl, M. Retroviral activation of the mir-106a microRNA cistron in T lymphoma. Retrovirology 2007, 4, 5.
106. Dabrowska, M.J.; Dybkaer, K.; Johnsen, H.E.; Wang, B.; Wabl, M.; Pedersen, F.S. Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J. Virol. 2009, 83, 8051-8061.
107. Li, J.; Shen, H.; Himmel, K.L.; Dupuy, A.J.; Largaespada, D.A.; Nakamura, T.; Shaughnessy, J.D., Jr.; Jenkins, N.A.; Copeland, N.G. Leukaemia disease genes: Large-scale cloning and pathway predictions. Nat. Genet. 1999, 23, 348-353.
108. Lund, A.H.; Turner, G.; Trubetskoy, A.; Verhoeven, E.; Wientjens, E.; Hulsman, D.; Russell, R.; DePinho, R.A.; Lenz, J.; van Lohuizen, M. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 2002, 32, 160-165.
109. Hwang, H.C.; Martins, C.P.; Bronkhorst, Y.; Randel, E.; Berns, A.; Fero, M.; Clurman, B.E. Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 11293-11298.
110. Suzuki, T.; Shen, H.; Akagi, K.; Morse, H.C.; Malley, J.D.; Naiman, D.Q.; Jenkins, N.A.; Copeland, N.G. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 2002, 32, 166-174.
111. Mattison, J.; Kool, J.; Uren, A.G.; de Ridder, J.; Wessels, L.; Jonkers, J.; Bignell, G.R.; Butler, A.; Rust, A.G.; Brosch, M.; et al. Novel candidate cancer genes identified by a large-scale crossspecies comparative oncogenomics approach. Cancer Res. 2010, 70, 883-895.
112. Makunin, I.V.; Pheasant, M.; Simons, C.; Mattick, J.S. Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse. PLoS ONE 2007, 2, e1133.
113. Miller, A.D. Retroviral vectors. Curr. Top. Microbiol. Immunol. 1992, 158, 1-24.
114. Matrai, J.; Chuah, M.K.; VandenDriessche, T. Recent advances in lentiviral vector development and applications. Mol. Ther. 18, 477-490.
115. Blaese, R.M.; Culver, K.W.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270, 475-480.
116. Ferrua, F.; Brigida, I.; Aiuti, A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 2010, 10, 551-556.
117. Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J.L.; Bousso, P.; Deist, F.L.; Fischer, A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288, 669-672.
118. Hacein-Bey-Abina, S.; Le Deist, F.; Carlier, F.; Bouneaud, C.; Hue, C.; De Villartay, J.P.; Thrasher, A.J.; Wulffraat, N.; Sorensen, R.; Dupuis-Girod, S.; et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002, 346, 1185-1193.
119. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415-419.
120. Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D.; et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118, 3143-3150.
121. Hacein-Bey-Abina, S.; von Kalle, C.; Schmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M.; Fischer, A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255-256.
122. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K.; et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118, 3132-3142.
123. Rabbitts, T.H.; Axelson, H.; Forster, A.; Grutz, G.; Lavenir, I.; Larson, R.; Osada, H.; Valge-Archer, V.; Wadman, I.; Warren, A. Chromosomal translocations and leukaemia: A role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis. Leukemia 1997, 11, 271-272.
124. Krause, D. Gene Therapy for Wiskott-Aldrich Syndrome: Benefits and Risks. Hematologist 2011, 1 March. Availale online: http://www.hematology.org/Publications/Hematologist/2011/6487.aspx (accessed on 17 March 2011).
125. Boztug, K.; Schmidt, M.; Schwarzer, A.; Banerjee, P.P.; Diez, I.A.; Dewey, R.A.; Bohm, M.; Nowrouzi, A.; Ball, C.R.; Glimm, H.; et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 2010, 363, 1918-1927.
126. Stein, S.; Ott, M.G.; Schultze-Strasser, S.; Jauch, A.; Burwinkel, B.; Kinner, A.; Schmidt, M.; Kramer, A.; Schwable, J.; Glimm, H.; et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010, 16, 198-204.
127. Yu, S.F.; von Ruden, T.; Kantoff, P.W.; Garber, C.; Seiberg, M.; Ruther, U.; Anderson, W.F.; Wagner, E.F.; Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 3194-3198.
128. Chung, J.H.; Whiteley, M.; Felsenfeld, G. A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993, 74, 505-514.
129. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004, 2, E234.
130. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521-529.
131. Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K.; et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467, 318-322.
132. Young, A.R.; Narita, M. Oncogenic HMGA2: Short or small? Genes Dev. 2007, 21, 1005-1009.